Health Care Fund
Daily price w/o sales charge as of 06/24/2022
$16.78
$0.37
YTD Returns w/o sales charge as of 06/24/2022
-15.72%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 05/31/2022
- Total Net Assets
- $6.46 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 3.75%
- Fund Net Expense Ratio
- 0.78%
- Number of Holdings
- 66
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -15.97% | -8.77% | - | - | - | 11.28% |
| Lipper Category Avg. Health/Biotechnology Funds | -18.49% | -13.52% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -8.04% | 1.20% | - | - | - | 12.82% |
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -7.68% | 1.88% | - | - | - | 16.04% |
| Lipper Category Avg. Health/Biotechnology Funds | -8.85% | -1.79% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -3.79% | 12.56% | - | - | - | 15.62% |
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -15.97% | -8.77% | - | - | - | 11.28% |
| Lipper Category Avg. Health/Biotechnology Funds | -18.49% | -13.52% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -8.04% | 1.20% | - | - | - | 12.82% |
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | -7.68% | 1.88% | - | - | - | 16.04% |
| Lipper Category Avg. Health/Biotechnology Funds | -8.85% | -1.79% | - | - | - | - |
| MSCI ACWI Health Care Index (Net) | -3.79% | 12.56% | - | - | - | 15.62% |
Fund Expense Ratio :
Gross 3.75%
Net 0.78%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
| Year | Fund Returns | MSCI ACWI Health Care Index (Net) |
|---|
| 2021 | 8.51% | 17.51% |
| 2020 | 37.39% | 14.87% |
| 2019 | 8.07% | 22.67% |
| Year | Q1 | Q2 | Q3 | Q4 | Yearly Returns |
|---|
| 2022 | -7.68% | - | - | - | -15.72% |
| 2021 | -1.67% | 7.21% | 0.43% | 2.49% | 8.51% |
| 2020 | -11.35% | 21.57% | 11.73% | 14.09% | 37.39% |
| 2019 | - | - | - | 16.29% | 8.07% |
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
Portfolio Details as of 05/31/2022
- Total Net Assets
- $6.46 M
- Number of Holdings
- 66
- Weighted Average Market Cap.
- 136.4 B
- P/B Ratio
- 5.8x
- P/E Ratio
- 23.4x
To view definitions for the above Portfolio Details, Click here.
| Holding | Sector | Assets |
|---|
| UnitedHealth Group Inc | Health Care | 6.2% |
| Eli Lilly & Co | Health Care | 5.2% |
| AstraZeneca PLC | Health Care | 4.8% |
| Novo Nordisk A/S | Health Care | 4.7% |
| Pfizer Inc | Health Care | 4.5% |
| Thermo Fisher Scientific Inc | Health Care | 4.0% |
| Merck & Co Inc | Health Care | 3.8% |
| Abbott Laboratories | Health Care | 3.0% |
| Danaher Corp | Health Care | 3.0% |
| Vertex Pharmaceuticals Inc | Health Care | 2.5% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| UnitedHealth Group Inc | Health Care | 5.8% |
| Roche Holding AG | Health Care | 5.1% |
| Novo Nordisk A/S | Health Care | 4.9% |
| AstraZeneca PLC | Health Care | 4.8% |
| Eli Lilly & Co | Health Care | 4.5% |
| Thermo Fisher Scientific Inc | Health Care | 3.8% |
| Danaher Corp | Health Care | 2.9% |
| Abbott Laboratories | Health Care | 2.8% |
| Vertex Pharmaceuticals Inc | Health Care | 2.5% |
| Zoetis Inc | Health Care | 2.2% |
| Edwards Lifesciences Corp | Health Care | 2.1% |
| Merck & Co Inc | Health Care | 2.0% |
| Intuitive Surgical Inc | Health Care | 2.0% |
| Humana Inc | Health Care | 1.9% |
| Pfizer Inc | Health Care | 1.8% |
| Dexcom Inc | Health Care | 1.6% |
| Alcon Inc | Health Care | 1.6% |
| Centene Corp | Health Care | 1.6% |
| HCA Healthcare Inc | Health Care | 1.5% |
| AmerisourceBergen Corp | Health Care | 1.5% |
| Genmab A/S | Health Care | 1.4% |
| Tenet Healthcare Corp | Health Care | 1.4% |
| Horizon Therapeutics Plc | Health Care | 1.4% |
| Lonza Group AG | Health Care | 1.4% |
| Insulet Corp | Health Care | 1.4% |
| Argenx SE | Health Care | 1.3% |
| Intra-Cellular Therapies Inc | Health Care | 1.2% |
| Cooper Cos Inc/The | Health Care | 1.2% |
| Cytokinetics Inc | Health Care | 1.2% |
| Krystal Biotech Inc | Health Care | 1.1% |
| Agilent Technologies Inc | Health Care | 1.1% |
| IDEXX Laboratories Inc | Health Care | 1.1% |
| Organon & Co | Health Care | 1.1% |
| Molina Healthcare Inc | Health Care | 1.0% |
| Zimmer Biomet Holdings Inc | Health Care | 1.0% |
| Lantheus Holdings Inc | Health Care | 1.0% |
| Inspire Medical Systems Inc | Health Care | 0.9% |
| BELLUS Health Inc | Health Care | 0.9% |
| West Pharmaceutical Services Inc | Health Care | 0.9% |
| Insmed Inc | Health Care | 0.9% |
| Neurocrine Biosciences Inc | Health Care | 0.8% |
| Repligen Corp | Health Care | 0.8% |
| Sanofi | Health Care | 0.8% |
| Biohaven Pharmaceutical Holding Co Ltd | Health Care | 0.8% |
| Seagen Inc | Health Care | 0.8% |
| Sarepta Therapeutics Inc | Health Care | 0.7% |
| Xenon Pharmaceuticals Inc | Health Care | 0.7% |
| Azenta Inc | Health Care | 0.6% |
| Karuna Therapeutics Inc | Health Care | 0.6% |
| UCB SA | Health Care | 0.6% |
| Sartorius Stedim Biotech | Health Care | 0.6% |
| Shockwave Medical Inc | Health Care | 0.6% |
| Rigel Pharmaceuticals Inc | Health Care | 0.5% |
| Outset Medical Inc | Health Care | 0.5% |
| Natera Inc | Health Care | 0.5% |
| Bio-Rad Laboratories Inc | Health Care | 0.5% |
| Anthem Inc | Health Care | 0.5% |
| Ultragenyx Pharmaceutical Inc | Health Care | 0.5% |
| CONMED Corp | Health Care | 0.5% |
| iRhythm Technologies Inc | Health Care | 0.5% |
| Axonics Inc | Health Care | 0.5% |
| BioCryst Pharmaceuticals Inc | Health Care | 0.5% |
| SpringWorks Therapeutics Inc | Health Care | 0.4% |
| Inari Medical Inc | Health Care | 0.4% |
| Penumbra Inc | Health Care | 0.4% |
| Merus NV | Health Care | 0.4% |
| Intellia Therapeutics Inc | Health Care | 0.4% |
| NGM Biopharmaceuticals Inc | Health Care | 0.3% |
| Doximity Inc | Health Care | 0.2% |
| Rocket Pharmaceuticals Inc | Health Care | 0.2% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Attribution Analysis
| Health Care Fund | Benchmark | Variance | |||||
|---|---|---|---|---|---|---|---|
| Sector | Avg. Weight | Base Return | Avg. Weight | Base Return | Stock Selection | Group Weight | Total |
The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to Lord Abbett International Core Fund Performance Results for the Fund's longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.
Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.
Contributors & Detractors as of 03/31/2022
Contributors
| Holding | Contribution |
|---|---|
| AstraZeneca PLC | 0.5% |
| Vertex Pharmaceutica | 0.3% |
| Intra Cellular Therapie | 0.2% |
| AmerisourceBergen Corp. | 0.2% |
| Novo Nordisk A/S | 0.1% |
Detractors
| Holding | Contribution |
|---|---|
| Natera Inc | -0.7% |
| Align Technology, Inc. | -0.6% |
| Zoetis Inc | -0.6% |
| Thermo Fisher Scientifi | -0.5% |
| 10x Genomics Inc | -0.4% |
Fees & Expenses
Fees & Expenses
Expense Ratioas of 05/31/2022
| Fund Gross Expense Ratio | Fund Net Expense Ratio | |
|---|---|---|
| 3.75% | 0.78% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2023. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
|
0Documents selected
|
Order | ||||
|---|---|---|---|---|---|
| n/a |
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
| n/a |
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
|
Summary Prospectus
Publish Date:11/03/2015
|
|||||
| n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
|||||
|
Annual Report
Publish Date:11/03/2015
|
|||||
|
Semi-Annual Report
Publish Date:11/03/2015
|
|||||
|
Fact Sheet
Publish Date:11/03/2015
|
|||||